Publicaciones en colaboración con investigadores/as de Universitat de València (10)

2023

  1. Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 2, pp. 389-400

2022

  1. Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study

    Cancers, Vol. 14, Núm. 19

2020

  1. Association between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women with Breast Cancer

    JAMA Dermatology, Vol. 156, Núm. 9, pp. 987-991

2019

  1. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Frontiers in Oncology, Vol. 9, Núm. APR

  2. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study

    Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125

2018

  1. Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy

    Oncotarget, Vol. 9, Núm. 41, pp. 26406-26416

2017

  1. A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse

    Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044

2016

  1. Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature

    Critical Reviews in Oncology/Hematology, Vol. 97, pp. 96-106

2012

  1. Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

    Oncologist, Vol. 17, Núm. 4, pp. 469-475

2006

  1. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen

    Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212